MARKET WIRE NEWS

BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline

Source: SeekingAlpha

2025-10-14 16:24:38 ET

The last time I spoke about BeOne Medicines AG ( ONC ), it was in a Seeking Alpha article entitled "BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion." With respect to this article, I noted that it had received a positive opinion from the CHMP, a European body, for its development of its PD-1 inhibitor TEVIMBRA so that it can expand its label to include the targeting of patients with untreated [1st-line] gastro/gastroesophageal junction cancer and 1st-line esophageal squamous cell carcinoma [ESCC patients]....

Read the full article on Seeking Alpha

For further details see:

BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline
BeiGene

NASDAQ: BEIGF

BEIGF Trading

0.0% G/L:

$23.75 Last:

100 Volume:

$23.75 Open:

mwn-alerts Ad 300

BEIGF Latest News

BEIGF Stock Data

$38,603,023,416
747,457,849
N/A
299
N/A
Biotechnology & Life Sciences
Healthcare
CH
Basel

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App